Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche announces European label extension for Avastin

Roche announces European label extension for Avastin

29th January 2008

Roche has announced that Avastin (bevacizumab), its anti-angiogenic agent for patients suffering from metastatic colorectal cancer, has received a broad label extension from the European Commission for wider use.

This label extension will enable the compound to be used in conjunction with any chemotherapy, including Xeloda (capecitabine), the oral chemotherapy from Roche, for first and later-line treatment for patients with metastatic colorectal cancer.

Prior to this label expansion Avastin could only be used as a combination treatment with IV 5-FU or IV 5-FU/irinotecan-based chemotherapy regimen where it had shown a survival extension of nearly five months.

William M Burns, member of the executive committee and chief executive officer of the pharmaceuticals division at Roche, said: “This is another milestone in our commitment to developing effective and safe treatments for the large number of colorectal cancer patients throughout the world.”

He added that the label expansion is extremely significant for the approximately 400,000 people diagnosed with the condition every year in Europe alone.

Last month, Roche announced that Avastin had been approved for use in combination with interferon in Europe for the first-line treatment of patients with advanced renal cell cancer.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.